Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Ironically enough, his initial downfall had nothing to do with Daraprim. Soon after he became infamous, federal prosecutors ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

"Spinogenix’s ALS hopeful to advance to registrational trial" was originally created and published by Clinical Trials Arena, ...

Last year, China-based Jiangsu Hengrui Pharmaceuticals overtook the U.K.’s AstraZeneca as the top clinical trial sponsor in ...

Drug Hunter, the leading knowledge platform for drug discovery R&D teams, today announced the appointment of Dr. Lori ...

Experts say that Tom Brady's decision to clone his family pet might not be worth the eye-watering $50,000 (£38,340) price tag ...

LANTANA, Fla., Nov. 5, 2025 /PRNewswire/ -- Industry leaders Scott Roberts and John "Zeke" Czekanski announced today they ...

The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.

After a three-month delay, the FDA has now rejected an approval request based on the RWE. According to Biohaven, the FDA’s complete response letter “cited issues that can be inherent to real-world ...

Biogen finds itself at a critical inflection point as the biotechnology firm attempts to secure a sustainable turnaround. The ...